everolimus

P1, N=50, Recruiting, University of California, San Francisco | Suspended --> Recruiting

P3, N=88, Completed, Centre Hospitalier Universitaire, Amiens | Unknown status --> Completed

CNI minimization - through basiliximab induction, low-dose tacrolimus with mycophenolate, or everolimus conversion - improves renal outcomes without compromising graft survival, despite trade-offs such as mild acute rejection or higher malignancy rates. Muñoz-Serrano et al retrospectively analyzed 594 liver transplant recipients over three decades to identify risk factors for CKD at one year post-transplant. The authors identified older age, female sex, pre-transplant renal dysfunction, and treatment with cyclosporine A as independent risk factors.

P1/2, N=435, Active, not recruiting, Stemline Therapeutics, Inc. | Recruiting --> Active, not recruiting

This case serves as a paradigm for mechanism-driven precision oncology, illustrating that everolimus monotherapy can achieve durable clinical benefit in NF1-deficient recurrent endometrial cancer, with remission persisting even after treatment discontinuation. These findings highlight the clinical relevance of comprehensive molecular diagnostics and support the integration of personalized treatment strategies into modern gynecologic oncology.

P2, N=50, Not yet recruiting, Jonsson Comprehensive Cancer Center

P2/3, N=60, Not yet recruiting, Boston Children's Hospital | Trial completion date: Apr 2030 --> Sep 2030 | Initiation date: Apr 2026 --> Sep 2026 | Trial primary completion date: Apr 2030 --> Sep 2030

Methods We derived a novel PDX from a patient with hormone receptor negative, HER2-positive IBC refractory to neoadjuvant chemotherapy with Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP)...We performed short-tandem repeat (STR) profiling, plotted tumor growth curves for mice treated with alpelisib/everolimus vs. untreated, and immunohistochemistry (IHC), and performed clinical genomic assays...Conclusion We established a PDX of a HER2-positive IBC tumor with a PIK3CA hotspot mutation (H1047R) refractory to TCHP. Targeting the PI3K/mTOR pathway may be useful to overcome resistance in HER2-positive IBC with a H1047R mutation in PIK3CA.

P2, N=94, Not yet recruiting, Yonsei University

Collectively, our analysis describes the driver genes and mutation characteristics in SCC. The multi-cohort and network-based framework employed in this study identifies candidate hub genes that warrant further clinical investigation in cervical cancer.

P1/2, N=12, Not yet recruiting, Centre Hospitalier De Versailles

In cisplatin-ineligible MIBC, the KEYNOTE-905/EV-303 trial demonstrated significant survival benefit with perioperative enfortumab vedotin plus pembrolizumab. In advanced RCC, KEYMAKER-U03 demonstrated improved progression-free survival with HIF-2α-based triplet therapy, the LenCabo study supported lenvatinib plus everolimus in later lines and the CALYPSO trial highlighted limited benefit of empiric combinations without biomarker selection. Emerging approaches including transcriptomic stratification (OPTIC RCC) and circulating biomarkers (KIM-1, ctDNA) support a shift toward biologically guided treatment selection.